GlobeNewswire Inc | Jan 4, 2022 08:00AM EST

January 04, 2022

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical stage biotechnology company focused on the development and commercialization of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an initial focus on inherited retinal diseases (IRDs), today announced that Sue Washer, President & Chief Executive Officer, and Susan Schneider M.D., Chief Medical Officer, will participate in a fireside chat at the H.C. Wainwright Virtual BioConnect Conference held January 10 13, 2022.

The fireside chat will be available to view on-demand beginning Monday, January 10, 2021 at 7:00AM ET through the entirety of the conference and available by visiting http://ir.agtc.com/events-and-presentations.

About AGTCAGTC is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases. AGTC is a leader in designing and constructing all critical gene therapy elements and bringing them together to develop customized therapies with the potential to address real patient needs. AGTCs most advanced clinical programs leverage its best-in-class technology platform to potentially improve vision for patients with an inherited retinal disease. AGTC has active clinical trials in X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM CNGB3 and ACHM CNGA3). Its preclinical programs build on the Companys industry leading AAV manufacturing technology and scientific expertise. AGTC is advancing multiple important pipeline candidates to address substantial unmet clinical need in optogenetics, otology and CNS disorders, including entering into strategic collaborations with companies including Otonomy, Inc., a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, and Bionic Sight, LLC, an innovator in the emerging field of optogenetics and retinal coding. For more information, please visit https://agtc.com/.

IR Contact:David Carey (IR)Lazar FINN PartnersT: (212) 867-1768david.carey@finnpartners.com

Corporate Contact:Jonathan LieberChief Financial OfficerApplied Genetic Technologies CorporationT: (617) 843-5778 jlieber@agtc.com